CSLLY News and Press, CSL Ltd ADR From 12/14/21

CSL (OTCPK:CSLLY -4.2%) to launch an all-cash public tender offer to acquire all publicly held Vifor Pharma shares for US$179.25 per Vifor Pharma share, for an aggregate equity value for Vifor Pharma of US$11.7 / A$16.4B. Patinex AG, Vifor Pharma's largest shareholder holding 23% of Vifo...

~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec ~ ~ Etranacogene dezaparvovec also achieved seconda...

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults PR Newswire SUMMIT, N.J. , Dec. 7, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza preventi...

Australian biotech company, CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), is reportedly in exclusive talks to buy Vifor Pharma (OTCPK:GNHAF) (OTCPK:GNHAY) for A$10 billion ($7.10 billion), The Australian newspaper said on Thursday, according to Reuters. Swiss drugmakers’ shar...

Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine PR Newswire SUMMIT, N.J. , Nov. 23, 2021 /PRNewswire/ -- The FDA has granted approval of multi-dose vial presentation for ...

CSL Plasma Opens 300th Plasma Donation Center in United States Greenacres, Florida, center opening exemplifies growing need for plasma donations, which enable production of plasma-derived medicines for patients in 100+ countries PR Newswire BOCA RATON, Fla. , O...

Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021 PR Newswire SUMMIT, N.J. , Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevent...

Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Hig...

Seqirus Receives FDA Approval of its Cell-Based Quadrivalent Influenza Vaccine, Expanding the Age Indication to Include Children as Young as Six Months - Approval aligns with universal age recommendation for all eligible people six months and older to receive annual influenza va...

The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) Efficacy in Children and Adolescents ≥2 to <18 Years of Age The New England Journal of Medicine Publishes First-of-its-Kind Study on Cell-...